Fiona J. Baird

Fiona J. Baird

Auto-generated profile, based on publicly available information

Fiona J. Baird

Centre for Biodiscovery & Molecular Development of Therapeutics, James Cook University, Townsville, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Microbiology
Verified
Journal Article
Open access
MSManvendra Saxena
Manvendra Saxena
TVThi Thu Hao Van
Thi Thu Hao Van
FBFiona J. Baird
Fiona J. Baird
PCPeter J. Coloe
Peter J. Coloe
PSPeter Smooker
Peter Smooker
Over the last century, the successful attenuation of multiple bacterial and viral pathogens has led to an effective, robust and safe form of vaccination. Recently, these vaccines have been evaluated as delivery vectors for heterologous antigens, as a means of simultaneous vaccination against two pathogens. The general consensus from published studies is that these vaccine vectors have the potential to be both safe and efficacious. However, some of the commonly employed vectors, for example Salmonella and adenovirus, often have pre-existing immune responses in the host and this has the potential to modify the subsequent immune response to a vectored antigen. This review examines the literature on this topic, and concludes that for bacterial vectors there can in fact, in some cases, be an enhancement in immunogenicity, typically humoral, while for viral vectors pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses.

1 August 2014 in Molecular and Cellular Probes
Verified
Journal Article
Open access
FBFiona J. Baird
Fiona J. Baird
RGRobin Gasser
Robin Gasser
Abdul JabbarAbdul Jabbar
Abdul Jabbar
Andreas Ludwig LopataAndreas Ludwig Lopata
Andreas Ludwig Lopata
Human anisakiasis, a disease caused by Anisakis spp. (Nematoda), is often associated with clinical signs that are similar to those associated with bacterial or viral gastroenteritis. With the globalisation of the seafood industry, the risk of humans acquiring anisakiasis in developed countries appears to be underestimated. The importance of this disease is not only in its initial manifestation, which can often become chronic if the immune response does not eliminate the worm, but, importantly, in its subsequent sensitisation of the human patient. This sensitisation to Anisakis-derived allergens can put the patient at risk of an allergic exacerbation upon secondary exposure. This article reviews some aspects of this food-borne disease and explains its link to chronic, allergic conditions in humans.

29 July 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FBFiona J. Baird
Fiona J. Baird
XSXiaopei Su
Xiaopei Su
IAIbukun Aibinu
Ibukun Aibinu
MNMatthew J. Nolan
Matthew J. Nolan
HSHiromu Sugiyama
Hiromu Sugiyama
CCCinzia Cantacessi
Cinzia Cantacessi
Food-borne nematodes of the genus Anisakis are responsible for a wide range of illnesses (= anisakiasis), from self-limiting gastrointestinal forms to severe systemic allergic reactions, which are often misdiagnosed and under-reported. In order to enhance and refine current diagnostic tools for anisakiasis, knowledge of the whole spectrum of parasite molecules transcribed and expressed by this parasite, including those acting as potential allergens, is necessary. In this study, we employ high-throughput (Illumina) sequencing and bioinformatics to characterise the transcriptomes of two Anisakis species, A. simplex and A. pegreffii, and utilize this resource to compile lists of potential allergens from these parasites. A total of ~65,000,000 reads were generated from cDNA libraries for each species, and assembled into ~34,000 transcripts (= Unigenes); ~18,000 peptides were predicted from each cDNA library and classified based on homology searches, protein motifs and gene ontology and biological pathway mapping. Using comparative analyses with sequence data available in public databases, 36 (A. simplex) and 29 (A. pegreffii) putative allergens were identified, including sequences encoding ‘novel’ Anisakis allergenic proteins (i.e. cyclophilins and ABA-1 domain containing proteins). This study represents a first step towards providing the research community with a curated dataset to use as a molecular resource for future investigations of the biology of Anisakis, including molecules putatively acting as allergens, using functional genomics, proteomics and immunological tools. Ultimately, an improved knowledge of the biological functions of these molecules in the parasite, as well as of their immunogenic properties, will assist the development of comprehensive, reliable and robust diagnostic tools. Nematodes within the genus Anisakis (i.e. A. simplex and A. pegreffii, also known as herring worms) are the causative agents of the fish-borne gastrointestinal illness known as ‘anisakiasis’, with infections resulting in symptoms ranging from mild gastric forms to severe allergic reactions leading to urticaria, gastrointestinal and/or respiratory signs and/or anaphylaxis (‘allergic anisakiasis’). Despite significant advances in knowledge of the pathobiology of allergic anisakiasis, thus far, the exact number and nature of parasite molecules acting as potential allergens are currently unknown; filling this gap is necessary to the development of robust and reliable diagnostics for allergic anisakiasis which, in turn, underpins the implementation of effective therapeutic strategies. Here, we use RNA-Seq and bioinformatics to sequence and annotate the transcriptomes of A. simplex and A. pegreffii, and, as an example application of these resources, mine this data to identify and characterise putative novel parasite allergens based on comparisons with known allergen sequence data from other parasites and other organisms.

12 May 2012 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
FBFiona J. Baird
Fiona J. Baird
MWMarilyn P. Wadsworth
Marilyn P. Wadsworth
JHJane E. Hill
Jane E. Hill

16 July 2014 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
FBFiona J. Baird
Fiona J. Baird
Andreas Ludwig LopataAndreas Ludwig Lopata
Andreas Ludwig Lopata
Traditional prophylactic vaccination to prevent illness is the primary objective of many research activities worldwide. The golden age of vaccination began with an approach called variolation in ancient China and the evolution of vaccines still continues today with modern developments such as the production of Gardasil™ against HPV and cervical cancer. The historical aspect of how different forms of vaccination have changed the face of medicine and communities is important as it dictates our future approaches on both a local and global scale. From the eradication of smallpox to the use of an experimental vaccine to save a species, this review will explore these successes in infectious disease vaccination and also discuss a few significant failures which have hampered our efforts to eradicate certain diseases. The second part of the review will explore designing a prophylactic vaccine for the growing global health concern that is allergy. Allergies are an emerging global health burden. Of particular concern is the rise of food allergies in developed countries where 1 in 10 children is currently affected. The formation of an allergic response results from the recognition of a foreign component by our immune system that is usually encountered on a regular basis. This may be a dust-mite or a prawn but this inappropriate immune response can result in a life-time of food avoidance and lifestyle restrictions. These foreign components are very similar to antigens derived from infectious pathogens. The question arises: should the allergy community be focussing on protective measures rather than ongoing therapeutic interventions to deal with these chronic inflammatory conditions? We will explore the difficulties and benefits of prophylactic vaccination against various allergens by means of genetic technology that will dictate how vaccination against allergens could be utilised in the near future.

1 April 2011 in Microbiology
Verified
Journal Article
Closed access
PDF file
EGEmily Gan
Emily Gan
FBFiona J. Baird
Fiona J. Baird
PCPeter J. Coloe
Peter J. Coloe
PSPeter Smooker
Peter Smooker
Salmonella enterica serovar Sofia (S. Sofia) is often isolated from chickens in Australia. However, despite its high frequency of isolation from chicken and chicken meat products, S. Sofia is rarely associated with animal or human salmonellosis, presumably because this serovar is avirulent in nature. The objective of this work was to investigate the phenotypic and molecular properties of S. Sofia in order to assess its pathogenic potential. Our in vivo studies support the observation that this serovar can colonize tissues, but does not cause disease in chickens. This was further confirmed with tissue culture assays, which showed that the ability of S. Sofia to adhere, invade and survive intracellularly is significantly diminished compared with the pathogenic Salmonella enterica serovar Typhimurium (S. Typhimurium) 82/6915. Molecular analysis of Salmonella pathogenicity islands (SPIs) showed that most of the differences observed in SPI1 to SPI5 of S. Sofia could be attributed to minor changes in the sequences, as indicated by a loss or gain of restriction cleavage sites within these regions. Sequence analysis demonstrated that the majority of virulence genes identified were predicted to encode proteins sharing a high identity (75–100 %) with corresponding proteins from S. Typhimurium. However, a number of virulence genes in S. Sofia have accumulated mutations predicted to affect transcription and/or translation. The avirulence of this serovar is probably not the result of a single genetic change but rather of a series of alterations in a large number of virulence-associated genes. The acquisition of any single virulence gene will almost certainly not be sufficient to restore S. Sofia virulence.